This study was designed to determine serum Fetuin-A levels and establish whether serum Fetuin-A level is related with insulin resistance, oxidative stress, ovarian hyperandrogenism and dyslipidemia in women with polycystic ovary syndrome (PCOS). Twenty-two patients with PCOS and twenty-one healthy control women were evaluated in this controlled clinical study. Serum Fetuin-A, lipid fractions, glucose, insulin, malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), superoxide dismutase (SOD) and other hormone (gonadotropins, androgens) levels were measured. The estimate of insulin resistance was calculated by homeostasis model assessment (HOMA-R). The women with PCOS had significantly higher serum fasting glucose, insulin, luteinizing hormone (LH), MDA, Fetuin-A levels, and LH/follicle-stimulating hormone (FSH) ratio, free androgen index (FAI), HOMA-IR than healthy women. However, sex hormone-binding globulin (SHBG) and GSH levels were significantly lower in patients with PCOS compared with controls. Fetuin-A was positively correlated with insulin, HOMA-IR and FAI. Multiple regression analysis revealed that FAI was strong predictor of serum Fetuin-A level. Serum Fetuin-A level was related with insulin resistance and ovarian hyperandrogenism in women with PCOS. These results suggest that Fetuin-A may have a role in triggering the processes leading to insulin resistance and androgen excess in PCOS.
1 December 2022 in Journal of Clinical Research in Pediatric Endocrinology
Children born small for gestational age (SGA) are at risk of future obesity and associated comorbidities. Therefore the identification of risk factors and novel biomarkers which are associated with this risk are needed for early detection and to improve preventive strategies. Spexin (SPX), a novel neuropeptide that is involved in the regulation of obesity and fat metabolism, is a candidate biomarker for predicting obesity and related comorbidities at an early age. The aim of this study was to investigate serum levels of SPX in term infants born small, appropriate, and large for gestational age (LGA) and its association with newborn anthropometric measurements. One hundred and twenty term newborn babies classified as SGA, appropriate for gestational age (AGA), or LGA and their mothers were included. SPX, leptin and visfatin were measured in cord blood and maternal serum by enzyme-linked immunosorbent assay. Fifty-six (46.7%) neonates were girls and 64 (53.3%) were boys. The mean birth weight was 3170.70±663 g, birth length was 48.9±2.79 cm, and head circumference was 34.5±1.67 cm. Birth weights, lengths, and head circumferences of the neonates in the SGA, AGA, and LGA groups were significantly different. Cord blood SPX and leptin levels in the SGA groups were significantly lower than those of both the LGA and AGA groups. Cord blood visfatin levels were significantly lower in the AGA group than the LGA and SGA groups. Maternal SPX levels of SGA babies were significantly lower than those of the mothers in both the LGA and AGA groups, but no significant difference was observed between the SGA and LGA groups. Maternal visfatin levels of the AGA babies were significantly higher than the maternal levels of SGA and LGA groups. There was no difference in terms of maternal leptin levels. Cord blood SPX and leptin levels were positively correlated with birth weight, length and head circumference. Birth weight increased significantly in line with maternal pregestational body mass index. The lowest SPX levels were found in the SGA babies and cord SPX level was significantly correlated with newborn length, weight, and head circumference.
14 October 2022 in Journal of Obstetrics and Gynaecology Research
Purpose: It is known that there is a two-way relationship in the etiopathogenesis of depression and obesity. This study aimed to investigate serum ghrelin, leptin, neuropeptide Y levels, cognitive functions, and atypical depressive features in obese and depressed patients. It is expected that obese and depressed patients will show similar features in terms of biochemical parameters and cognitive functions, and atypical depressive features may be high in obese individuals. Materials and methods: The study included 56 obese individuals, 60 patients with major depressive disorder (MDD), and 53 healthy controls (HC). The questionnaires administered included socio-demographic data form, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Dutch Eating Behaviour Questionnaire, Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD). Cognitive functions were assessed with short computer version of Wisconsin Card Sorting Test (WCST), Berg’s WCST, Stroop Colour-Word Test-Victoria version. Serum ghrelin, leptin, and neuropeptide Y levels were measured. Results: The depression scores were found higher MDD group than obesity and HC groups (p0.05). Differences were detected between the groups in the Stroop test. Leptin levels were higher (p<0.001), ghrelin (p=0.038) and neuropeptide Y (p<0.001) levels lower in obesity group compared to MDD and HC. Ghrelin levels negatively correlated with total number of incorrect responses in terms of cognitive functions in obese individuals (r=-0.259 p=0.049). Conclusion: In our study, it was determined that although depressive symptoms were high in obesity, there were no atypical depressive features, executive functions were similar between the groups, and neurochemical marker levels were not similar in obesity and depression. Our results do not support the relationship between obesity and atypical depression.
7 September 2021 in Journal of Obstetrics and Gynaecology Research